Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma
Aliment Pharmacol Ther 2010; 32: 851–858 Summary Background Hepatocellular carcinoma (HCC) is third most common cause of tumour‐related death in the US with hepatitis C virus (HCV) the most common aetiology. Surgical resection and tumour ablation are curative in patients who cannot be transplanted....
Gespeichert in:
| Veröffentlicht in: | Alimentary pharmacology & therapeutics 2010-10, Vol.32 (7), p.851-858 |
|---|---|
| Hauptverfasser: | , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 858 |
|---|---|
| container_issue | 7 |
| container_start_page | 851 |
| container_title | Alimentary pharmacology & therapeutics |
| container_volume | 32 |
| creator | Singal, A. K. Freeman Jr, D. H. Anand, B. S. |
| description | Aliment Pharmacol Ther 2010; 32: 851–858
Summary
Background Hepatocellular carcinoma (HCC) is third most common cause of tumour‐related death in the US with hepatitis C virus (HCV) the most common aetiology. Surgical resection and tumour ablation are curative in patients who cannot be transplanted. With native liver having cirrhosis, HCC recurrence is a potential problem.
Aim To perform a systematic review and meta‐analysis of studies evaluating efficacy of IFN to prevent HCC recurrence after its curative treatment in HCV‐related cirrhosis.
Methods Ten studies (n = 645, 301 treated with IFN) on the use of IFN after resection or ablation of HCV‐associated HCC were analysed.
Results Pooled data showed benefit of IFN for HCC prevention with OR (95% CI) of 0.26 (0.15–0.45); P |
| doi_str_mv | 10.1111/j.1365-2036.2010.04414.x |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_874194073</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>753994955</sourcerecordid><originalsourceid>FETCH-LOGICAL-c5464-1e713f6d2f33390ac0e3cfa9cd88a9893c11be378b2479cdf292a58761ed3f13</originalsourceid><addsrcrecordid>eNqNkc9uEzEQxi1ERdPCK6C9IE4b_HdtI3GoKmiRWsEhd2vi2ODIuw72Lm1uPALPyJPUS0I5gi8zHv_G82k-hBqCl6SeN9slYZ1oKWbdkuJaxZwTvrx_ghaPD0_RAtNOt1QRdorOStlijDuJ6TN0SnEnNFVigcKtG-HXj58wQNyXUN42YRhd9i6noQn9LqfvrjRpGm3qa-JTjOkuDF8aWEcYQ4VSbrIrzh4uvvnqdjAm62KcIuTGQrZhSD08RyceYnEvjvEcrT68X11etzefrj5eXty0VvCOt8RJwny3oZ4xpjFY7Jj1oO1GKdBKM0vI2jGp1pTLWvVUUxBKdsRtmCfsHL0-fFulf5tcGU0fyqwGBpemYpTkRHMs2T9JKZjWXAtRSXUgbU6lZOfNLoce8t4QbGZDzNbMezfz3s1siPltiLmvrS-PQ6Z17zaPjX8cqMCrIwDFQvQZBhvKX44RyQTpKvfuwN2F6Pb_LcBcfF7NGXsA8RmpHg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>753994955</pqid></control><display><type>article</type><title>Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma</title><source>Wiley Online Library - AutoHoldings Journals</source><source>MEDLINE</source><source>Wiley Online Library</source><source>EZB Electronic Journals Library</source><creator>Singal, A. K. ; Freeman Jr, D. H. ; Anand, B. S.</creator><creatorcontrib>Singal, A. K. ; Freeman Jr, D. H. ; Anand, B. S.</creatorcontrib><description>Aliment Pharmacol Ther 2010; 32: 851–858
Summary
Background Hepatocellular carcinoma (HCC) is third most common cause of tumour‐related death in the US with hepatitis C virus (HCV) the most common aetiology. Surgical resection and tumour ablation are curative in patients who cannot be transplanted. With native liver having cirrhosis, HCC recurrence is a potential problem.
Aim To perform a systematic review and meta‐analysis of studies evaluating efficacy of IFN to prevent HCC recurrence after its curative treatment in HCV‐related cirrhosis.
Methods Ten studies (n = 645, 301 treated with IFN) on the use of IFN after resection or ablation of HCV‐associated HCC were analysed.
Results Pooled data showed benefit of IFN for HCC prevention with OR (95% CI) of 0.26 (0.15–0.45); P < 0.00001. The proportion of patients surviving at 5 years (n = 505 in 6 studies) was in favour of IFN with OR of 0.31 [(95% CI 0.21–0.46); P < 0.00001]. Data were homogeneous for HCC recurrence (χ2 12.05, P = 0.21) and survival (χ2 6.93, P = 0.44). The benefit of IFN was stronger with sustained virological response compared with nonresponders for HCC recurrence [0.19 (0.06–0.60); P = 0.005] and survival [0.31 (0.11–0.90); P = 0.03].
Conclusion Interferon treatment after curative resection or ablation of HCC in HCV‐related cirrhotics prevents HCC recurrence and improves survival.</description><identifier>ISSN: 0269-2813</identifier><identifier>EISSN: 1365-2036</identifier><identifier>DOI: 10.1111/j.1365-2036.2010.04414.x</identifier><identifier>PMID: 20659285</identifier><language>eng</language><publisher>Oxford, UK: Blackwell Publishing Ltd</publisher><subject>Antiviral Agents - therapeutic use ; Biological and medical sciences ; Carcinoma, Hepatocellular - drug therapy ; Carcinoma, Hepatocellular - surgery ; Digestive system ; Gastroenterology. Liver. Pancreas. Abdomen ; Hepatectomy ; Hepatitis C virus ; Hepatitis C, Chronic - complications ; Hepatitis C, Chronic - drug therapy ; Humans ; Interferons - therapeutic use ; Liver Cirrhosis - complications ; Liver Cirrhosis - drug therapy ; Liver Neoplasms - drug therapy ; Liver Neoplasms - surgery ; Liver. Biliary tract. Portal circulation. Exocrine pancreas ; Medical sciences ; Pharmacology. Drug treatments ; Secondary Prevention ; Treatment Outcome ; Tumors</subject><ispartof>Alimentary pharmacology & therapeutics, 2010-10, Vol.32 (7), p.851-858</ispartof><rights>2010 Blackwell Publishing Ltd</rights><rights>2015 INIST-CNRS</rights><rights>2010 Blackwell Publishing Ltd.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c5464-1e713f6d2f33390ac0e3cfa9cd88a9893c11be378b2479cdf292a58761ed3f13</citedby><cites>FETCH-LOGICAL-c5464-1e713f6d2f33390ac0e3cfa9cd88a9893c11be378b2479cdf292a58761ed3f13</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fj.1365-2036.2010.04414.x$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fj.1365-2036.2010.04414.x$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,1427,27901,27902,45550,45551,46384,46808</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=23173516$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20659285$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Singal, A. K.</creatorcontrib><creatorcontrib>Freeman Jr, D. H.</creatorcontrib><creatorcontrib>Anand, B. S.</creatorcontrib><title>Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma</title><title>Alimentary pharmacology & therapeutics</title><addtitle>Aliment Pharmacol Ther</addtitle><description>Aliment Pharmacol Ther 2010; 32: 851–858
Summary
Background Hepatocellular carcinoma (HCC) is third most common cause of tumour‐related death in the US with hepatitis C virus (HCV) the most common aetiology. Surgical resection and tumour ablation are curative in patients who cannot be transplanted. With native liver having cirrhosis, HCC recurrence is a potential problem.
Aim To perform a systematic review and meta‐analysis of studies evaluating efficacy of IFN to prevent HCC recurrence after its curative treatment in HCV‐related cirrhosis.
Methods Ten studies (n = 645, 301 treated with IFN) on the use of IFN after resection or ablation of HCV‐associated HCC were analysed.
Results Pooled data showed benefit of IFN for HCC prevention with OR (95% CI) of 0.26 (0.15–0.45); P < 0.00001. The proportion of patients surviving at 5 years (n = 505 in 6 studies) was in favour of IFN with OR of 0.31 [(95% CI 0.21–0.46); P < 0.00001]. Data were homogeneous for HCC recurrence (χ2 12.05, P = 0.21) and survival (χ2 6.93, P = 0.44). The benefit of IFN was stronger with sustained virological response compared with nonresponders for HCC recurrence [0.19 (0.06–0.60); P = 0.005] and survival [0.31 (0.11–0.90); P = 0.03].
Conclusion Interferon treatment after curative resection or ablation of HCC in HCV‐related cirrhotics prevents HCC recurrence and improves survival.</description><subject>Antiviral Agents - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>Carcinoma, Hepatocellular - drug therapy</subject><subject>Carcinoma, Hepatocellular - surgery</subject><subject>Digestive system</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Hepatectomy</subject><subject>Hepatitis C virus</subject><subject>Hepatitis C, Chronic - complications</subject><subject>Hepatitis C, Chronic - drug therapy</subject><subject>Humans</subject><subject>Interferons - therapeutic use</subject><subject>Liver Cirrhosis - complications</subject><subject>Liver Cirrhosis - drug therapy</subject><subject>Liver Neoplasms - drug therapy</subject><subject>Liver Neoplasms - surgery</subject><subject>Liver. Biliary tract. Portal circulation. Exocrine pancreas</subject><subject>Medical sciences</subject><subject>Pharmacology. Drug treatments</subject><subject>Secondary Prevention</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><issn>0269-2813</issn><issn>1365-2036</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqNkc9uEzEQxi1ERdPCK6C9IE4b_HdtI3GoKmiRWsEhd2vi2ODIuw72Lm1uPALPyJPUS0I5gi8zHv_G82k-hBqCl6SeN9slYZ1oKWbdkuJaxZwTvrx_ghaPD0_RAtNOt1QRdorOStlijDuJ6TN0SnEnNFVigcKtG-HXj58wQNyXUN42YRhd9i6noQn9LqfvrjRpGm3qa-JTjOkuDF8aWEcYQ4VSbrIrzh4uvvnqdjAm62KcIuTGQrZhSD08RyceYnEvjvEcrT68X11etzefrj5eXty0VvCOt8RJwny3oZ4xpjFY7Jj1oO1GKdBKM0vI2jGp1pTLWvVUUxBKdsRtmCfsHL0-fFulf5tcGU0fyqwGBpemYpTkRHMs2T9JKZjWXAtRSXUgbU6lZOfNLoce8t4QbGZDzNbMezfz3s1siPltiLmvrS-PQ6Z17zaPjX8cqMCrIwDFQvQZBhvKX44RyQTpKvfuwN2F6Pb_LcBcfF7NGXsA8RmpHg</recordid><startdate>201010</startdate><enddate>201010</enddate><creator>Singal, A. K.</creator><creator>Freeman Jr, D. H.</creator><creator>Anand, B. S.</creator><general>Blackwell Publishing Ltd</general><general>Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>7T5</scope><scope>7U9</scope><scope>H94</scope></search><sort><creationdate>201010</creationdate><title>Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma</title><author>Singal, A. K. ; Freeman Jr, D. H. ; Anand, B. S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c5464-1e713f6d2f33390ac0e3cfa9cd88a9893c11be378b2479cdf292a58761ed3f13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Antiviral Agents - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>Carcinoma, Hepatocellular - drug therapy</topic><topic>Carcinoma, Hepatocellular - surgery</topic><topic>Digestive system</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Hepatectomy</topic><topic>Hepatitis C virus</topic><topic>Hepatitis C, Chronic - complications</topic><topic>Hepatitis C, Chronic - drug therapy</topic><topic>Humans</topic><topic>Interferons - therapeutic use</topic><topic>Liver Cirrhosis - complications</topic><topic>Liver Cirrhosis - drug therapy</topic><topic>Liver Neoplasms - drug therapy</topic><topic>Liver Neoplasms - surgery</topic><topic>Liver. Biliary tract. Portal circulation. Exocrine pancreas</topic><topic>Medical sciences</topic><topic>Pharmacology. Drug treatments</topic><topic>Secondary Prevention</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Singal, A. K.</creatorcontrib><creatorcontrib>Freeman Jr, D. H.</creatorcontrib><creatorcontrib>Anand, B. S.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>Immunology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><jtitle>Alimentary pharmacology & therapeutics</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Singal, A. K.</au><au>Freeman Jr, D. H.</au><au>Anand, B. S.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma</atitle><jtitle>Alimentary pharmacology & therapeutics</jtitle><addtitle>Aliment Pharmacol Ther</addtitle><date>2010-10</date><risdate>2010</risdate><volume>32</volume><issue>7</issue><spage>851</spage><epage>858</epage><pages>851-858</pages><issn>0269-2813</issn><eissn>1365-2036</eissn><abstract>Aliment Pharmacol Ther 2010; 32: 851–858
Summary
Background Hepatocellular carcinoma (HCC) is third most common cause of tumour‐related death in the US with hepatitis C virus (HCV) the most common aetiology. Surgical resection and tumour ablation are curative in patients who cannot be transplanted. With native liver having cirrhosis, HCC recurrence is a potential problem.
Aim To perform a systematic review and meta‐analysis of studies evaluating efficacy of IFN to prevent HCC recurrence after its curative treatment in HCV‐related cirrhosis.
Methods Ten studies (n = 645, 301 treated with IFN) on the use of IFN after resection or ablation of HCV‐associated HCC were analysed.
Results Pooled data showed benefit of IFN for HCC prevention with OR (95% CI) of 0.26 (0.15–0.45); P < 0.00001. The proportion of patients surviving at 5 years (n = 505 in 6 studies) was in favour of IFN with OR of 0.31 [(95% CI 0.21–0.46); P < 0.00001]. Data were homogeneous for HCC recurrence (χ2 12.05, P = 0.21) and survival (χ2 6.93, P = 0.44). The benefit of IFN was stronger with sustained virological response compared with nonresponders for HCC recurrence [0.19 (0.06–0.60); P = 0.005] and survival [0.31 (0.11–0.90); P = 0.03].
Conclusion Interferon treatment after curative resection or ablation of HCC in HCV‐related cirrhotics prevents HCC recurrence and improves survival.</abstract><cop>Oxford, UK</cop><pub>Blackwell Publishing Ltd</pub><pmid>20659285</pmid><doi>10.1111/j.1365-2036.2010.04414.x</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0269-2813 |
| ispartof | Alimentary pharmacology & therapeutics, 2010-10, Vol.32 (7), p.851-858 |
| issn | 0269-2813 1365-2036 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_874194073 |
| source | Wiley Online Library - AutoHoldings Journals; MEDLINE; Wiley Online Library; EZB Electronic Journals Library |
| subjects | Antiviral Agents - therapeutic use Biological and medical sciences Carcinoma, Hepatocellular - drug therapy Carcinoma, Hepatocellular - surgery Digestive system Gastroenterology. Liver. Pancreas. Abdomen Hepatectomy Hepatitis C virus Hepatitis C, Chronic - complications Hepatitis C, Chronic - drug therapy Humans Interferons - therapeutic use Liver Cirrhosis - complications Liver Cirrhosis - drug therapy Liver Neoplasms - drug therapy Liver Neoplasms - surgery Liver. Biliary tract. Portal circulation. Exocrine pancreas Medical sciences Pharmacology. Drug treatments Secondary Prevention Treatment Outcome Tumors |
| title | Meta‐analysis: interferon improves outcomes following ablation or resection of hepatocellular carcinoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-07T18%3A10%3A28IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Meta%E2%80%90analysis:%20interferon%20improves%20outcomes%20following%20ablation%20or%20resection%20of%20hepatocellular%20carcinoma&rft.jtitle=Alimentary%20pharmacology%20&%20therapeutics&rft.au=Singal,%20A.%20K.&rft.date=2010-10&rft.volume=32&rft.issue=7&rft.spage=851&rft.epage=858&rft.pages=851-858&rft.issn=0269-2813&rft.eissn=1365-2036&rft_id=info:doi/10.1111/j.1365-2036.2010.04414.x&rft_dat=%3Cproquest_cross%3E753994955%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=753994955&rft_id=info:pmid/20659285&rfr_iscdi=true |